星期三盤前交易時段，丹納赫公司（NYSE: DHR）股價下跌。公司報告第四季度調整後每股收益爲$2.14，未達到預期的$2.16。季度銷售額爲$65.4億（+2%），高於分析師預期的$64.2億。 生物技術部門季度同比增長6.5%，而生命科學部門增長5.5%。診斷部門銷售額同比下降3%。 公司以$20.78億的現金及等價物和$23.30億的庫存結束了本季度。 丹納赫的長期債務截止季度末總計$155億。第四季度經營現金流爲$20億，非GAAP自由現金流爲$15億。 總裁兼首席執行官Rainer M. Blair表示：“我們團隊的良好執行也推動了強勁的現金流和營業利潤率擴展。” 展望未來，丹納赫預計第一季度非GAAP核心收入將同比下降低個位數百分比。 然而，公司預計2025年全年核心收入將同比增長3%。 Blair繼續說道：“展望未來，我們認爲丹納赫比我們40年曆史中的任何時候都處於更好的位置。” “我們近幾年在投資組合中的轉型使我們成爲專注的生命科學和診斷創新者，準備實現更高的長期增長，擴展利潤率和更強的現金流。” 上市後價格變動：截至週三最後檢查，DHR股價盤前下跌5.48%，至$234.26。

以上內容來自Benzinga Earnings專欄，原文如下：

Danaher Corporation (NYSE:DHR) shares are trading lower in the premarket session on Wednesday.

The company reported fourth-quarter adjusted earnings per share of $2.14 missing the street view of $2.16. Quarterly sales of $6.54 billion (+2%) beat the analyst consensus estimate of $6.42 billion.

The Biotechnology segment gained 6.5% year over year in the quarter under review, while the Life Sciences segment rose 5.5%. The Diagnostics segment sales decreased by 3% year over year.

The company exited the quarter with cash and equivalents worth $2.078 billion, and inventories worth $2.330 billion.

Also Read: Nasdaq Jumps 2% After Nvidia, Other Tech Stocks Bounce Back From DeepSeek Hit: Greed Index Remains In ‘Fear’ Zone

Danaher’s long-term debt as of quarter end totaled $15.50 billion. Operating cash flow was $2.0 billion in the fourth quarter and non-GAAP free cash flow was $1.5 billion.

Rainer M. Blair, President and Chief Executive Officer, stated, “Good execution by our team also drove solid cash flow and operating margin expansion.”

Outlook: Danaher expects its non-GAAP core revenue to decline by a low-single digit percentage year-over-year in the first quarter.

However, it anticipates a 3% year-over-year increase in core revenue for the full year of 2025.

Blair continued, “Looking ahead, we believe Danaher is better positioned than at any point in our 40-year history”. 

“The transformation in our portfolio over the last several years has created a focused life sciences and diagnostics innovator, poised for higher long-term growth, expanded margins and stronger cash flow.”

Price Action: DHR shares are trading lower by 5.48% to $234.26 premarket at last check Wednesday.

Read Next:

• Jim Cramer Recommends Buying ‘Fabulous' BlackRock, Calls Coterra Energy The ‘Cheapest' Natural Gas Company

Photo via Shutterstock.